Celgene Corporation (CELG) Receives Media Sentiment Score of 0.18
Media headlines about Celgene Corporation (NASDAQ:CELG) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celgene Corporation earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.2934497454113 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Better Buy: Celgene Corporation vs. Merck & Co., Inc. – Madison.com (host.madison.com)
- Ardsley Advisory Partners Buys Alexion Pharmaceuticals Inc, New Residential Investment Corp, … (nasdaq.com)
- Juno Tenders $250M Follow-on Public Offering of Common Stock (finance.yahoo.com)
- Robert W. Baird Reiterates Buy Rating for Celgene Corporation (CELG) (americanbankingnews.com)
CELG has been the subject of a number of analyst reports. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 6th. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, June 8th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, June 7th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 6th. Finally, Mizuho boosted their target price on shares of Celgene Corporation from $130.00 to $134.00 and gave the stock a “buy” rating in a research note on Thursday, June 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $149.34.
Shares of Celgene Corporation (CELG) opened at 143.89 on Friday. The firm has a market capitalization of $112.57 billion, a price-to-earnings ratio of 44.56 and a beta of 1.89. The stock has a 50 day moving average of $135.45 and a 200 day moving average of $127.81. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $144.19.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the previous year, the firm earned $1.44 EPS. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.
In related news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 63,006 shares of company stock worth $8,490,806 over the last quarter. Insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/23/celgene-corporation-celg-receives-media-sentiment-score-of-0-18.html.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.